

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige et al.

10/666,696 Serial No.:

Group Art Unit No.: 1642

Filed:

September 19, 2003

Examiner: S. Huff

For:

MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527H

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted.

Timothy J. Gadí 🗸

Attorney for Applicants Registration No.: 33,111

Phone: (805) 447-2688

Date: December 18,2003

Please send all future correspondence to: US Patent Operations/ [TJG] Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

"Express Mail" mail tabeling number: EV352488785US

EXPRESS MAIL CERTIFICATE

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OIPE 1 8 2000 G		Sheet 1 Of 2
Modified Form PTO-1449	Atty. Docket No.	Serial No.
	A-527H	10/666.696
LIST OF REFERENCES CITED BY APPLICANT	Applicant	
ZIO I DE MANDE MAN	Feige et al.	
(Use several sheets if necessary)	Filing Date	Group
•	September 19,	2003 1642_

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME .	CLASS	· SUB- Class	FILING DATE IF APPROPRIATE
	A1	5,521,073	05/28/96	Davis et al.			
	A2	5,643,755	07/01/97	Davis et al.			
	A3	5,650,490	07/22/97	Davis et al.			-
	A4	5,814,464	09/29/98	Davis et al.			-
	A 5	5,879,672	03/09/99	Davis et al.			
	A6	5,955,291	09/21/99	Alitalo et al.			
	A7	5,972,338	10/26/99	Godowski et al.			
	A8	6,030,831	02/29/00	Godowski et al.			
	A9	6,166,185	12/26/00	Davis et al.		-,	
	A10	6,323,323	11/27/01	Sledziewski et al.			

FOREIGN PATENT DOCUMENTS

		COCHMENT MIMBED	DATE	COLINTOV	U Yee	CLASS	TDANCI YES	NO NO
	B1	WO 95/13387	05/18/95	PCT				
	B2	WO 95/21866	08/17/95	PCT				
~	B3	WO 98/05779	02/12/98	PCT			·	
_/	B4	WO 98/18914	05/07/98	PCT				
1	B5	WO 99/43801	09/02/99	PCT				
/	В6	WO 00/57901	10/05/00	PCT				
/	B7	WO 00/06195	02/10/00	PCT				
/	B8	WO 00/75323	12/14/00	PCT				
/	B9	WO 00/77037	12/21/00	PCT				
/	B10	WO 01/62891	8/30/01	PCT		-		
						_		

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if a communication to applicant.	not in conformance and not considered. Include copy of this form with next

DEC 1 8 2003 &			Sheet	2	Of	2
Modified Form PTO-1449	Atty. Docket No.		Serial No.			
2 .67		A-527H	}	10/666	6.696	
LIST OF REFERENCES THED BY APPLICANT	Applicant					
EIST OF THE ENERGES STEED BY ALL EISANT		Feige et al.				
(Use several sheets if necessary)	Filing Date		Group			
		September 19, 2003		1642		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Officit BooomEleto (moldaling Addition, files, Bate, Fortimone Fagos, Elen)
	C1	Connell et al. (2001), "Patent Focus on Cancer Chemotherapeutics. III Angiogenesis Agents: October 2000 - March 2001," Ashley Publications Ltd. ISSN 1354-3776, pp. 1171-1203.
` _	C2	Coxon et al. (2002), "Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis," <i>Arthritis Rheum</i> . 46:2604-2612.
)	C3	Feige et al. (2000), "Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats," <i>Cell Mol. Life Sci.</i> 57:1457-1470.
)	C4	Peacock et al. (1992), "Angiogenesis inhibition suppresses collagen arthritis," J. Exp. Med. 175:1135-1138.
	C5	Peacock et al. (1995), "A novel angiogenesis inhibitor suppresses rat adjuvant arthritis," <i>Cell Immunol.</i> 160:178-184.
	C6	Walsh et al. (2001), "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res.</i> 3:147-153.
		·
		·
	-	
Ц		

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if n	ot in conformance and not considered. Include copy of this form with next